Cynthia Brinson

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

Chloe Orkin, Keikawus Arastéh, Miguel Górgolas Hernández-Mora et al. · New England Journal of Medicine · 2020 · 464 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Kenneth H. Mayer, Jean‐Michel Molina, Melanie Thompson et al. · The Lancet · 2020 · 424 citations · Full text

Public Health, Pharmacology, Pharmacotherapy +17

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 381 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies

Josep M. Llibre, Chien‐Ching Hung, Cynthia Brinson et al. · The Lancet · 2018 · 347 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19

Anil Kumar Gupta, Yaneicy Gonzalez‐Rojas, Erick Stanley Petersen Juárez et al. · JAMA · 2022 · 294 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +12